Id |
Subject |
Object |
Predicate |
Lexical cue |
T123 |
0-96 |
Sentence |
denotes |
We need better data to determine risk factors and mechanisms that cause SARS-CoV-2 reactivation. |
T124 |
97-256 |
Sentence |
denotes |
The timing of onset of SARS-CoV-2 reactivation can be variable depending upon the host factors, underlying disease and the type of immunosuppressive therapies. |
T125 |
257-343 |
Sentence |
denotes |
In our study, the recovered patients had positive RT-PCR test results 4–17 days later. |
T126 |
344-494 |
Sentence |
denotes |
The key risk factors for reactivation would include 3 categories: (1) host status, (2) virologic factors and (3) type and degree of immunosuppression. |
T127 |
495-578 |
Sentence |
denotes |
Host factors may include sex, older age, type of disease needing immunosuppression. |
T128 |
579-725 |
Sentence |
denotes |
Although we could not identify risk factors for these host factors in the current study, the potential requires further large cohort confirmation. |
T129 |
726-855 |
Sentence |
denotes |
The virologic factors associated with increased risk of reactivation include high baseline SARS-CoV-2 load and variable genotype. |
T130 |
856-1079 |
Sentence |
denotes |
SARS-CoV-2 viral load would also linked to treatment response, disease severity and progression.8 The association of SARS-CoV-2 genotypes and viral load with SARS-CoV-2 reactivation will be an important question to address. |
T131 |
1080-1163 |
Sentence |
denotes |
In our study, all the patients received antiviral therapy (Oseltamivir or Arbidol). |
T132 |
1164-1259 |
Sentence |
denotes |
These cases suggest that SARS-CoV-2 reactivation may occur whatever the antiviral therapy used. |
T133 |
1260-1390 |
Sentence |
denotes |
These host and virologic factors are important considerations that may further increase the likelihood of SARS-CoV-2 reactivation. |
T134 |
1391-1565 |
Sentence |
denotes |
Therefore, the assessment of host as well as virologic risk factors should be important caveats to help decide whether to initiate prophylactic therapy and immunosuppression. |
T135 |
1566-1633 |
Sentence |
denotes |
Immunosuppressive therapies are the commonly used causative agents. |
T136 |
1634-1708 |
Sentence |
denotes |
These agents have a general mechanism that inhibits many immune functions. |
T137 |
1709-1998 |
Sentence |
denotes |
For example, steroid inhibits cell-mediated immunity by suppressing interleukins production which is important for T and B cell proliferation.9 It is thus not surprising that these general immunosuppressive effects result in broad immune dysfunctions and potential SARS-CoV-2 reactivation. |